Ultrasound-guided platelet-rich plasma injections for post-traumatic greater occipital neuralgia: study protocol for a pilot randomized controlled trial
| dc.contributor.author | Stone, Jacqueline E. | |
| dc.contributor.author | Fung, Tak S. | |
| dc.contributor.author | Machan, Matthew | |
| dc.contributor.author | Campbell, Christina | |
| dc.contributor.author | Shan, Rodney L. P. | |
| dc.contributor.author | Debert, Chantel T. | |
| dc.date.accessioned | 2021-06-27T00:02:31Z | |
| dc.date.available | 2021-06-27T00:02:31Z | |
| dc.date.issued | 2021-06-22 | |
| dc.date.updated | 2021-06-27T00:02:30Z | |
| dc.description.abstract | Abstract Background Post-traumatic headaches (PTH) are a common sequelae of traumatic brain injury (TBI) and greatly impact patient function and quality of life. Post-traumatic greater occipital neuralgia (GON) is a type of post-traumatic headache. Conventional treatment includes steroid/anesthetic injections which typically alleviate pain but have a short duration of effect. Platelet-rich plasma (PRP) is an emerging biological treatment for numerous degenerative disorders, including peripheral nerve disorders. The primary aim of this pilot study is to evaluate whether a randomized control trial of PRP for the treatment of GON in patients with post-traumatic headaches is feasible in regard to recruitment, adherence, retention, and adherence and adverse events. Exploratory aims include improvement in pain, function, and quality of life in patients with post-traumatic GON receiving PRP compared to steroid/anesthetic and normal saline injections. Methods Thirty adults (over 18 years of age) with post-traumatic GON will be randomized into one of three groups: (1) autologous PRP injection, (2) steroid/anesthetic injection (standard care), or (3) placebo injection with normal saline. Injections will be performed to the greater occipital nerve under ultrasound guidance by a trained physician. Daily headache intensity and frequency data will be collected pre-injection and for the duration of the study period. Feasibility will be defined as greater than 30% recruitment, 70% completion of intervention, 70% retention, and less than 2 minor adverse events. Exploratory outcomes will be explored using the Headache Impact Test-6 (HIT-6, a valid and reliable 6-item questionnaire for assessment of the impact of headaches across different diagnostic groups of headaches) and the quality of life in following brain injury questionnaire (QOILIBRI). Discussion This pilot study will be the first to evaluate the feasibility of PRP as a potential treatment of GON in patients with post-traumatic headache. Trial registration ClinicalTrials.gov - NCT04051203 (registered August 9, 2019). | |
| dc.identifier.citation | Pilot and Feasibility Studies. 2021 Jun 22;7(1):130 | |
| dc.identifier.doi | https://doi.org/10.1186/s40814-021-00867-3 | |
| dc.identifier.uri | http://hdl.handle.net/1880/113544 | |
| dc.identifier.uri | https://doi.org/10.11575/PRISM/44390 | |
| dc.language.rfc3066 | en | |
| dc.rights.holder | The Author(s) | |
| dc.title | Ultrasound-guided platelet-rich plasma injections for post-traumatic greater occipital neuralgia: study protocol for a pilot randomized controlled trial | |
| dc.type | Journal Article |